![VJHemOnc Podcast](https://pbcdn1.podbean.com/imglogo/image-logo/8189927/VJH_Thumbnail_1400b48w2.jpg)
58.4K
Downloads
272
Episodes
The Video Journal of Hematology and Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com
Episodes
![CLL therapy: the latest trial updates and innovative novel therapies for the future](https://pbcdn1.podbean.com/imglogo/image-logo/8189927/VJH_Thumbnail_1400b48w2_300x300.jpg)
Sunday Sep 20, 2020
Sunday Sep 20, 2020
Recent clinical trials studying novel therapeutic strategies to target chronic lymphocytic leukemia (CLL) have brought a spotlight to their potential as alternatives to traditional chemotherapy. Here we bring you an overview and discussion on the latest trial updates, including CLL12, CLL14, RESONATE, ASCEND, among others.
This podcast features Patrick Thornton from Beaumont Hospital, Dublin; Petra Langerbeins of the University of Cologne, Germany; Alessandra Tedeschi from Niguarda Cancer Center, Milan, Italy; Susan O’Brien of the University of California; Paolo Ghia of Università Vita-Salute San Raffaele, Milan, Italy; Othman Al-Sawaf of University Hospital Cologne, Germany; Arnon Kater from the University of Amsterdam; and Tanya Siddiqi of the City of Hope, California. The footage featured is from the European Hematology Association (EHA) 2019, held in Amsterdam, The Netherlands, and the International Conference on Malignant Lymphoma (ICML) 2019 in Lugano, Switzerland.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.